- Home
- RARE vs ENS Comparison
RARE vs ENS Comparison
Compare RARE & ENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- ENS
- Stock Information
- Founded
- RARE 2010
- ENS 1991
- Country
- RARE United States
- ENS United States
- Employees
- RARE N/A
- ENS N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- ENS Industrial Machinery/Components
- Sector
- RARE Health Care
- ENS Technology
- Exchange
- RARE Nasdaq
- ENS Nasdaq
- Market Cap
- RARE 3.5B
- ENS 3.3B
- IPO Year
- RARE 2014
- ENS N/A
- Fundamental
- Price
- RARE $36.68
- ENS $85.79
- Analyst Decision
- RARE Strong Buy
- ENS Strong Buy
- Analyst Count
- RARE 15
- ENS 2
- Target Price
- RARE $90.53
- ENS $117.50
- AVG Volume (30 Days)
- RARE 1.1M
- ENS 524.8K
- Earning Date
- RARE 07-31-2025
- ENS 08-06-2025
- Dividend Yield
- RARE N/A
- ENS 1.12%
- EPS Growth
- RARE N/A
- ENS 38.31
- EPS
- RARE N/A
- ENS 8.99
- Revenue
- RARE $590,689,000.00
- ENS $3,617,579,000.00
- Revenue This Year
- RARE $18.94
- ENS $2.47
- Revenue Next Year
- RARE $28.93
- ENS $3.32
- P/E Ratio
- RARE N/A
- ENS $9.56
- Revenue Growth
- RARE 33.46
- ENS 1.00
- 52 Week Low
- RARE $29.59
- ENS $76.57
- 52 Week High
- RARE $60.37
- ENS $112.53
- Technical
- Relative Strength Index (RSI)
- RARE 51.86
- ENS 47.71
- Support Level
- RARE $36.03
- ENS $80.82
- Resistance Level
- RARE $37.74
- ENS $88.07
- Average True Range (ATR)
- RARE 1.46
- ENS 1.66
- MACD
- RARE -0.01
- ENS 0.21
- Stochastic Oscillator
- RARE 26.56
- ENS 49.85
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About ENS EnerSys
EnerSys provides stored energy solutions for industrial applications. It also manufactures and distributes energy systems solutions and motive power batteries, specialty batteries, battery chargers, power equipment, battery accessories, and outdoor equipment enclosure solutions to customers. Energy Systems that combine enclosures, power conversion, power distribution, and energy storage are used in the telecommunication and broadband, utility industries, uninterruptible power supplies, and numerous applications requiring stored energy solutions. Its segments include Energy Systems, Motive Power, and Specialty.